Andrew Steinsapir

Andrew Steinsapir is Gene Therapy Program Lead, Deerfield Discovery and Development, and joined Deerfield in 2021. Prior to Deerfield, Mr. Steinsapir was a Consultant for over three years at Dark Horse Consulting Group, where he provided strategic and tactical support for more than 30 cell and gene therapy firms, pharma, and investment firms. Previous to Dark Horse, Mr. Steinsapir worked at 4D Molecular Therapeutics for over three years, holding various positions, with his most recent role being Senior Process Development Associate I. Mr. Steinsapir holds a B.S. in Chemical Engineering with an emphasis on Biotechnology from the University of California, Berkeley.